Narcolepsy Patients Prefer Once-Nightly Lumryz Over Twice-Nightly Oxybate
Summary: Avadel Pharmaceuticals plc announced the publication of final data from the RESTORE open-label/switch study, which demonstrated a strong preference among people with narcolepsy for the once-nightly Lumryz over a twice-nightly immediate-release oxybate. Lumryz, approved by the FDA in 2023 as the first and only once-nightly oxybate, was overwhelmingly favored by participants for its convenience…